Genexine Past Earnings Performance

Past criteria checks 0/6

Genexine's earnings have been declining at an average annual rate of -45.5%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 61.1% per year.

Key information

-45.5%

Earnings growth rate

-39.3%

EPS growth rate

Biotechs Industry Growth	11.7%
Revenue growth rate	-61.1%
Return on equity	-22.5%
Net Margin	-1,510.7%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

Recent updates

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

Revenue & Expenses Breakdown
Beta

How Genexine makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A095700 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	4,427	-66,874	14,008	26,330
30 Sep 23	5,200	-107,828	19,182	33,093
30 Jun 23	7,224	-105,681	15,800	29,553
31 Mar 23	6,019	-96,287	16,096	26,661
31 Dec 22	16,139	-55,974	15,911	26,445
30 Sep 22	15,807	-50,558	13,330	28,044
30 Jun 22	13,662	-48,074	12,331	28,416
31 Mar 22	14,678	-52,957	10,986	31,184
31 Dec 21	36,828	-48,042	10,143	33,118
30 Sep 21	43,311	584	9,282	35,260
30 Jun 21	43,745	51,242	8,840	39,862
31 Mar 21	43,803	63,816	8,438	39,881
31 Dec 20	18,543	27,570	7,997	39,206
30 Sep 20	13,752	-4,016	8,023	38,286
30 Jun 20	17,214	-47,325	8,420	33,649
31 Mar 20	18,290	-61,230	8,928	38,480
31 Dec 19	11,303	-16,509	9,151	40,449
30 Sep 13	4,460	-5,989	8,683	0

Quality Earnings: A095700 is currently unprofitable.

Growing Profit Margin: A095700 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A095700 is unprofitable, and losses have increased over the past 5 years at a rate of 45.5% per year.

Accelerating Growth: Unable to compare A095700's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A095700 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).

Return on Equity

High ROE: A095700 has a negative Return on Equity (-22.52%), as it is currently unprofitable.

Genexine Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Recent updates

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta